(Q39232767)

10 September 2017

1 reference

title

Interleukin-2 in cancer treatment: disappointing or (still) promising? A review (English)

1 reference

10 September 2017

R A Maas

1

1 reference

10 September 2017

H F Dullens

series ordinal

2

1 reference

10 September 2017

W Den Otter

series ordinal

3

1 reference

10 September 2017

publication date

1 January 1993

1 reference

Cancer Immunology, Immunotherapy

10 September 2017

published in

1 reference

10 September 2017

volume

36

1 reference

10 September 2017

issue

3

1 reference

10 September 2017

page(s)

141-148

1 reference

https://scigraph.springernature.com/pub.10.1007/bf01741084

10 September 2017

exact match

0 references

cites work

The clinical effects of prolonged treatment of patients with advanced cancer with low-dose subcutaneous interleukin-2 [corrected]

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FBF01741084

Application of an interleukin 2 slow delivery system to the immunotherapy of established murine colon 26 adenocarcinoma liver metastases

21 January 2018

1 reference

12 December 2020

Heterogeneity of helper/inducer T lymphocytes. I. Lymphokine production and lymphokine responsiveness

1 reference

12 December 2020

In vivo antitumor activity of tumor-infiltrating lymphocytes expanded in recombinant interleukin-2.

1 reference

12 December 2020

Phase II trial of outpatient interleukin-2 in malignant lymphoma, chronic lymphocytic leukemia, and selected solid tumors

1 reference

12 December 2020

Local interleukin-2 therapy in bovine ocular squamous cell carcinoma

1 reference

12 December 2020

Growth inhibition of an MC-induced mouse sarcoma by TCGF (IL 2)-containing preparations. Preliminary report

1 reference

12 December 2020

Interleukin 2 and lymphokine-activated killer cell therapy: analysis of a bolus interleukin 2 and a continuous infusion interleukin 2 regimen

1 reference

12 December 2020

Structure of the gene of tum- transplantation antigen P198: a point mutation generates a new antigenic peptide

1 reference

12 December 2020

Eradication of disseminated murine leukemia by treatment with high-dose interleukin 2

1 reference

12 December 2020

The requirements for successful immunotherapy of intraperitoneal cancer using interleukin-2 and lymphokine-activated killer cells

1 reference

12 December 2020

Treatment of recurrent squamous cell carcinoma of the head and neck with low doses of interleukin-2 injected perilymphatically

1 reference

12 December 2020

IL-6 and IL-1 synergize to stimulate IL-2 production and proliferation of peripheral T cells.

1 reference

12 December 2020

In vivo activity of solid phase interleukin 2

1 reference

12 December 2020

A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma

1 reference

12 December 2020

Pharmacokinetics of recombinant interleukin 2 in humans

1 reference

12 December 2020

Recombinant interleukin-2 directly augments the cytotoxicity of human monocytes

1 reference

12 December 2020

Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients

1 reference

12 December 2020

Analysis of the murine lymphokine-activated killer (LAK) cell phenomenon: dissection of effectors and progenitors into NK- and T-like cells.

1 reference

12 December 2020

Granulocyte colony-stimulating factor gene transfer suppresses tumorigenicity of a murine adenocarcinoma in vivo

1 reference

12 December 2020

Lymphocytes as cellular vehicles for gene therapy in mouse and man.

1 reference

12 December 2020

Toxicity and therapeutic efficacy of high-dose interleukin 2. In vivo infusion of antibody to NK-1.1 attenuates toxicity without compromising efficacy against murine leukemia

1 reference

12 December 2020

Long term culture of tumour-specific cytotoxic T cells

1 reference

12 December 2020

Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: analysis of toxicity and management guidelines

1 reference

12 December 2020

Adoptive Immunotherapy of Established Pulmonary Metastases with LAK Cells and Recombinant Interleukin-2

1 reference

12 December 2020

Interleukin-2 dose, blood monocyte and CD25+ lymphocyte counts as predictors of clinical response to interleukin-2 therapy in patients with renal cell carcinoma

1 reference

12 December 2020

Clinical and immunological effects of recombinant interleukin 2 given by repetitive weekly cycles to patients with cancer.

1 reference

12 December 2020

Correlation between clinical response to interleukin 2 therapy and sustained production of tumor necrosis factor

1 reference

12 December 2020

Successful immunotherapy of murine experimental hepatic metastases with lymphokine-activated killer cells and recombinant interleukin 2.

1 reference

12 December 2020

Local and systemic effects during interleukin-2 therapy of mouse mammary tumors

1 reference

12 December 2020

Cytokine regulation of tumor necrosis factor-alpha and -beta (lymphotoxin)-messenger RNA expression in human peripheral blood mononuclear cells

1 reference

12 December 2020

A phase II study of interleukin-2 and lymphokine-activated killer cells in patients with metastatic malignant melanoma

1 reference

12 December 2020

Induction of endogenous cytokine-mRNA in circulating peripheral blood mononuclear cells by IL-2 administration to cancer patients.

1 reference

12 December 2020

Clinical effects and toxicity of interleukin-2 in patients with cancer

1 reference

12 December 2020

Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression

1 reference

12 December 2020

Retroviral vector-mediated gamma-interferon gene transfer into tumor cells generates potent and long lasting antitumor immunity

1 reference

12 December 2020

In vivo induction of IL-6 by administration of exogenous cytokines and detection of de novo serum levels of IL-6 in tumor-bearing mice

1 reference

12 December 2020

Lymphokine-activated killer (LAK) cells. II. Delineation of distinct murine LAK-precursor subpopulations.

1 reference

12 December 2020

Lymphokine-activated tumor inhibition in vivo. I. The local administration of interleukin 2 triggers nonreactive lymphocytes from tumor-bearing mice to inhibit tumor growth.

1 reference

12 December 2020

Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer

1 reference

12 December 2020

Interleukin 2-mediated immune interferon (IFN-gamma) production by human T cells and T cell subsets

1 reference

12 December 2020

In vitro growth of murine T cells. V. The isolation and growth of lymphoid cells infiltrating syngeneic solid tumors.

1 reference

12 December 2020

Monocyte interleukin 2 receptor gene expression and interleukin 2 augmentation of microbicidal activity

1 reference

12 December 2020

Tumour regression after intralesional injection of interleukin 2 (IL-2) in bladder cancer. Preliminary report

1 reference

12 December 2020

A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes

1 reference

12 December 2020

Tumor localization of adoptively transferred indium-111 labeled tumor infiltrating lymphocytes in patients with metastatic melanoma

1 reference

12 December 2020

Recombinant interleukin 2 or 5, but not 3 or 4, induces maturation of resting mouse B lymphocytes and propagates proliferation of activated B cell blasts

1 reference

12 December 2020

Interleukin 2 receptors on human B cells. Implications for the role of interleukin 2 in human B cell function

1 reference

12 December 2020

Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report

1 reference

12 December 2020

Increased vascular permeability in organs mediated by the systemic administration of lymphokine-activated killer cells and recombinant interleukin-2 in mice

1 reference

12 December 2020

Increased local antitumor effects of interleukin 2 liposomes in mice with MCA-106 sarcoma pulmonary metastases

1 reference

12 December 2020

The anti-tumour efficacy of human recombinant interleukin 2. Correlation between sensitivity of tumours to the cytolytic effect of LAK cells in vitro and their susceptibility to interleukin 2 immunotherapy in vivo

1 reference

12 December 2020

IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells

1 reference

12 December 2020

Adoptive immunotherapy of human cancer: the cytokine cascade and monocyte activation following high-dose interleukin 2 bolus treatment

1 reference

12 December 2020

Lack of correlation between peripheral blood lymphokine-activated killer (LAK) cell function and clinical response in patients with advanced malignant melanoma receiving recombinant interleukin 2.

1 reference

12 December 2020

Therapy of renal cell carcinoma with interleukin-2 and lymphokine-activated killer cells: phase II experience with a hybrid bolus and continuous infusion interleukin-2 regimen

1 reference

12 December 2020

Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three district histological types

1 reference

12 December 2020

Cytolytic potential of peripheral blood T-lymphocytes following adoptive immunotherapy with lymphokine-activated killer cells and low-dose interleukin 2

1 reference

12 December 2020

The IL-2 receptor beta chain (p70): role in mediating signals for LAK, NK, and proliferative activities

1 reference

12 December 2020

T-cell-derived helper factor allows in vivo induction of cytotoxic T cells in nu/nu mice

1 reference

12 December 2020

Generation of cytotoxic lymphocytes to syngeneic tumor by using co-stimulator (Interleukin 2)

1 reference

12 December 2020

Adoptive immunotherapy of human cancer using low-dose recombinant interleukin 2 and lymphokine-activated killer cells

1 reference

12 December 2020

Immunohistochemical correlates of response to recombinant interleukin-2-based immunotherapy in humans

1 reference

12 December 2020

Immunotherapy of a murine tumor with interleukin 2. Increased sensitivity after MHC class I gene transfection

1 reference

12 December 2020

Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins

1 reference

12 December 2020

Recombinant interleukin-2 and lymphokine-activated killer cell treatment of advanced bladder cancer: clinical results and immunological effects

1 reference

12 December 2020

Cancer treatment with interleukins 1, 4 and 6 and combinations of cytokines: a review.

1 reference

12 December 2020

Intralesional infusion of lymphokine-activated killer (LAK) cells and recombinant interleukin-2 (rIL-2) for the treatment of patients with malignant brain tumor

1 reference

12 December 2020

Production of interferon gamma, interleukin 2, interleukin 4, and interleukin 10 by CD4+ lymphocytes in vivo during healing and progressive murine leishmaniasis

1 reference

12 December 2020

Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer

1 reference

12 December 2020

Augmentation of specific immune response against a syngeneic SV40-induced sarcoma in mice by depletion of suppressor T cells with cyclophosphamide

1 reference

12 December 2020

Schedule dependency of the antitumor activity and toxicity of polyethylene glycol-modified interleukin 2 in murine tumor models.

1 reference

12 December 2020

Intraperitoneal lymphokine-activated killer-cell and interleukin-2 therapy for malignancies limited to the peritoneal cavity

1 reference

12 December 2020

Interference of anti-tumor and immunosuppressive effects of cyclophosphamide in tumor-bearing rats. Analysis of factors determining resistance or susceptibility to a subsequent tumor challenge

1 reference

12 December 2020

Systematic preclinical study on the therapeutic properties of recombinant human interleukin 2 for the treatment of metastatic disease.

1 reference

12 December 2020

Intratumoral low-dose interleukin-2 induces rejection of distant solid tumour

1 reference

12 December 2020

Interleukin 2-activated human killer cells are derived from phenotypically heterogeneous precursors.

1 reference

12 December 2020

Continuous interleukin-2 and lymphokine-activated killer cells for advanced cancer: a National Biotherapy Study Group trial

1 reference

12 December 2020

Cardiorespiratory effects of immunotherapy with interleukin-2.

1 reference

12 December 2020

Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response

1 reference

12 December 2020

Immunotherapy of mice with a large burden of disseminated lymphoma with low-dose interleukin 2.

1 reference

12 December 2020

The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells

1 reference

12 December 2020

Natural killer cells activated by interleukin 2 treatment in vivo respond to interleukin 2 primarily through the p75 receptor and maintain the p55 (TAC) negative phenotype

1 reference

12 December 2020

Murine interleukin-4 displays potent anti-tumor activity in vivo

1 reference

12 December 2020

Tumor suppression after tumor cell-targeted tumor necrosis factor alpha gene transfer

1 reference

12 December 2020

Interleukin 2-dependent activation of tumor-specific cytotoxic T lymphocytes in vivo.

1 reference

12 December 2020

Local administration of autologous lymphokine-activated killer cells and recombinant interleukin 2 to patients with malignant brain tumors.

1 reference

12 December 2020

The activation of IL-2 transcription in L3T4+ and Lyt-2+ lymphocytes during virus infection in vivo.

1 reference

12 December 2020

Interleukin-2 therapy in patients with metastatic malignant melanoma: a phase II study

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF01741084

1 reference

10 September 2017

1 reference